Sevelamer carbonate reduces the risk of hypomagnesemia in hemodialysis-requiring end-stage renal disease patients
Conclusions
Hemodialysis patients receiving sevelamer show higher serum magnesium levels and a reduced risk of hypomagnesemia. This effect remains even after adjustment for PPI use. This effect could contribute to the still controversial superiority of sevelamer in preventing vascular calcifications.
Source: CKJ: Clinical Kidney Journal - Category: Urology & Nephrology Authors: Rosa-Diez, G., Negri, A. L., Crucelegui, M. S., Philippi, R., Perez-Teysseyre, H., Sarabia-Reyes, C., Loor-Navarrete, H., Heguilen, R. Tags: DIALYSIS Source Type: research
More News: Dialysis | Hemodialysis | Magnesium | Proton Pump Inhibitors PPIs | Renvela | Urology & Nephrology